Demography, Pattern of Care, and Survival in Patients with Xanthoastrocytoma: A Systematic Review and Individual Patient Data Analysis of 325 Cases

Supriya Mallick¹ Prashanth Giridhar¹ Rony Benson¹ Wineeta Melgandi¹ Goura Kishor Rath¹

¹Department of Radiation Oncology, B.R.A. Institute-Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Address for correspondence Rony Benson, Department of Radiation Oncology, B.R.A. Institute-Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India (e-mail: ronybenson@gmail.com).

Abstract

Objectives Xanthoastrocytoma (XA) is a low-grade glial tumor seen in young adults, and there is lack of robust data on treatment of this rare tumor. In this systematic review and individual patient’s data analysis, we aimed to look into the demography, pattern of care, survival outcomes, and prognostic factors in patients with both Grade II and III XA.

Methods A comprehensive search was conducted with the Medical Subject Heading terms: “Xanthoastrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Xanthoastrocytoma; Xanthoastrocytoma AND treatment; and Anaplastic Xanthoastrocytoma AND survival” to find all possible publications.

Results A total of 325 individual patients from a total of 138 publications pertaining to XA were retrieved. Median age of the entire cohort was 19 years. About 56.1% of the patients underwent a gross total resection (GTR) and 31.4% underwent a subtotal resection. Nearly, 76.6% of the patients had a Grade II tumor and adjuvant radiation was delivered in 27.4% of the patients. Estimated 2- and 5-year progression-free survival (PFS) were 68.5 and 51.2%, respectively. Age, grade, and extent of surgery were significant factors affecting PFS. Estimated 2- and 5-year overall survival (OS) was 88.8 and 78%, respectively. The median OS for Grade II and Grade III tumors were 209 and 49 months, respectively. Age and extent of surgery were significant factors affecting OS.

Conclusion XA is a disease of young adults with favorable prognosis. Younger patients (<20 years), patients who undergo a GTR, and patients with a lower grade tumor have a better treatment outcome.

Keywords ► meta-analysis ► survival ► xanthoastrocytoma

Introduction

Xanthoastrocytoma (XA) was first described by Kepes et al in 1979 as a low-grade glial tumor seen in young adults. XA usually presents with seizures and includes Grade II and Grade III tumors with distinct clinical behavior. Though most of the tumors are reported to arise from temporal lobe, these tumors have been reported to arise from any part of the central nervous system. Maximal safe surgical resection is often considered the cornerstone of therapy. Adjuvant therapy though advocated by many lacks consensus and merits a relook. However, the greatest limitation is the sporadic reporting of XA in the literature. In the absence of robust data, treatments are often based on local expertise and institutional protocol extrapolating data of other common glial tumors. Our earlier analysis was limited to patients of Grade II XA.¹ In this systematic review and individual patient’s data analysis, we aimed to look into the demography, pattern of care, survival outcomes, and prognostic factors in patients with both Grade II and III XA.

DOI https://doi.org/10.1055/s-0039-1697873
ISSN 0976-3147.

©2019 Association for Helping Neurosurgical Sick People

License terms
Methods

Search Methodology
A comprehensive search was conducted in the PubMed, Google Scholar with the Medical Subject Heading terms: “Xanthoastrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Xanthoastrocytoma; Xanthoastrocytoma AND treatment; and Anaplastic Xanthoastrocytoma AND survival” to find all possible publications. After retrieving the titles of such articles, we sorted out any unrelated articles. We retrieved full-length articles of those remaining to finalize articles for data extraction. In addition, we searched the references in those articles as well to fetch any article missing after the search. Thereafter, duplicates were removed, and the remaining articles were looked into detail. Patient data were extracted and entered in a predesigned excel chart with the headings of “age, gender, presenting complaints, type of surgery, radiation use, chemotherapy, recurrence, duration of progression-free interval, salvage treatment, death, and survival.” Articles that did not report treatment and outcome were excluded from the analysis. Once the data extraction was complete, it was rechecked by the individual authors to look for errors or duplication. A total of 138 articles were retrieved pertaining to XA with 325 patients. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart (Fig. 1) explains the data synthesis from the eligible studies.

Statistical Analysis
The data were analyzed and categorical variables were summarized by frequency and percentage and quantitative variables by the median and range. Progression-free survival (PFS) and overall survival (OS) were calculated from the date of diagnosis to the date of documented progression or death. Kaplan–Meier method was used to for survival analysis. Cox regression model was used for multivariate analysis. Factors with p-value < 0.1 were included in the multivariate analysis. A p-value < 0.05 was taken as significant. SPSS Inc., Released 2007, SPSS for Windows, Version 16.0, Chicago, Illinois, United States was used for all statistical analysis.

Results
We retrieved data of 325 individual patients from a total of 138 publications pertaining to XA. Median age of the entire cohort was 19 years (range: 0.9–84 years). More than fourth (82%) of the patients were diagnosed within the fourth decade. Of these 325 patients, incidence of XA was equally distributed among males and females with a ratio of 0.92:1 favoring females. Nearly half of the patients presented with features of raised intracranial pressure (47%) followed by seizure which was the presenting symptom in one-third of the patients. Out of 325 patients, 118 (36.3%) patients had tumor located in the temporal lobe only followed by multilobar (16%) disease and frontal lobe (9.8%). A total of 8 patients had tumor located in different parts of the spinal cord as well. Only two patients had leptomeningeal dissemination at diagnosis. Patient characteristics are summarized in Table 1.

Treatment
Surgical details were available in 287 cases. Of these, 161 (56.1%) patients underwent a gross total resection (GTR) and 90 (31.4%) patients underwent a subtotal resection. Histologic grade was available in 218 cases. Of these, 167 (76.6%) patients had a Grade II tumor and the remaining 23.4% patients had a Grade III tumor. Median K–67 was found to be 5.6% (range: 1–33.2%). In 14 patients (58.3%) out of 24 available cases, BRAF mutation was noted. Adjuvant radiation was delivered in 77 (27.4%) patients, whereas 1 patient was treated with palliative radiation and salvage radiation was used in 19 (6.8%) patients. In the available reports, all patients received local radiation alone. Adjuvant chemotherapy was used in 37 (14.9%) patients. Chemotherapy regimen varied widely; but in the recent report, temozolomide has been found to be the preferred choice (n = 7).

Survival Outcome
Estimated 2- and 5-year PFS were 68.5 and 51.2%, respectively. In univariate analysis, younger patients (≤20 years) found to have better PFS compared with elder patients (> 20 years) (hazard ratio [HR] 2.26 [95% confidence interval [CI]: 1.3–4.0], p = 0.006). Patients with a GTR had a significantly better PFS than those treated with a subtotal resection (STR) only (HR 2.19 [95% CI: 1.1–4.2], p = 0.019). PFS was found to be significantly better for those with a Grade II tumor compared with those with a Grade III tumor (HR 3.18 [95% CI: 1.6–6.4], p = 0.001) (Fig. 2). Age, grade, and extent of surgery continued to be significant in multivariate analysis with HR of 1.9 (95% CI: 1.2–8.2, p = 0.007), 2.0 (95% CI: 1.2–3.3, p = 0.005), and 1.9 (95% CI: 1.1–3.2, p = 0.018), respectively.
Estimated 2- and 5-year OS were 88.8 and 78%, respectively. In univariate analysis, younger patients (≤20 years) were found to have better OS compared with elder patients (>20 years) (HR 1.58 [95% CI: 1.07–2.32], p = 0.019). Patients with a GTR had a significantly better OS than those treated with a STR only (HR 1.72 [95% CI: 1.1–2.71], p = 0.017). OS was found to be significantly better for those with a Grade II tumor compared with those with a Grade III tumor (HR 2.2 [95% CI: 1.4–3.6], p = 0.001) (►Fig. 3). The median OS for Grade II and Grade III tumors were 209 and 49 months, respectively. The other factors such as sex, adjuvant chemotherapy, and adjuvant radiotherapy had no impact on OS. Age and extent of surgery continued to be significant in multivariate analysis with HR of 3.4 (95% CI: 1.4–8.4, p = 0.005) and 2.8 (95% CI: 1.3–6.3, p = 0.010), respectively. Grade of tumor lost its statistical significance in multivariate analysis.

Pattern of Recurrence and Salvage Treatment
Status of disease progression was documented in 275 patients. At a median follow-up of 32.4 months, 130 patients experienced disease progression. Most common pattern of recurrence was local but 9 (6.9%) patients had leptomeningeal dissemination. Details of salvage therapy were available in 76 (58.5%) patients. About 26.3% patients underwent a repeat surgery alone, and 17.1% patients received radiation as salvage treatment. However, a total of 54 (71.1%) patients underwent surgery followed by observation or other form of therapy as well. Of these 76 patients, 51 (67.1%) patients received radiation either alone or in combination with surgery and chemotherapy. Interestingly, only 5 of these 51 patients had received prior radiation. Salvage chemotherapy has been used in 30 (39.5%) patients. Chemotherapy regimen varied widely from temozolomide, bevacizumab, carmustine, lapa
tinib, irinotecan, flutamide, lomustine, cyclophosphamide,

### Table 1 Demographic features and patterns of care in patients with pleomorphic xanthoastrocytoma

| Patient characteristics | Number of patients (percentage)/(range) |
|-------------------------|----------------------------------------|
| Age                     | Median: 19 y (range: 0.9–84)           |
| Sex (n = 318)           | Male: 153                               |
|                         | Female: 165                             |
|                         | Male:female ratio: 0.93:1              |
| Presenting symptoms (n = 229) | Seizure: 108 (47.2%)                  |
|                         | Headache: 76 (33.2%)                   |
|                         | Sensory symptoms: 26 (11.4%)           |
|                         | Motor symptoms: 16 (6.9%)              |
|                         | Hemorrhage: 3 (1.3%)                   |
| Radiological feature (n = 61) | Cystic: 44 (72.1%)                     |
|                         | Solid: 10 (16.4%)                      |
|                         | Solid-cystic: 7 (11.5%)                |
|                         | Contrast enhancement: 35(57.3%)        |
| K-67 labeling index (n = 54) | Median: 5.6% (range: 1–33.2%)         |
| Surgery (n = 287)       | Gross total or near total resection: 161 (56.1%) |
|                         | Subtotal resection or debulking: 90 (31.4%) |
|                         | Biopsy: 6 (2.1%)                       |
| Grade (n = 218)         | Grade II: 167 (76.6%)                   |
|                         | Grade III: 51 (23.4%)                  |
| BRAF mutation (N = 24)  | Yes: 14 (58.3%)                        |
|                         | No: 10 (41.7%)                         |
| Radiation (N = 281)     | Adjuvant radiation: 77 (27.4%)         |
|                         | No adjuvant radiation: 184 (65.5%)     |
|                         | Palliative: 1 (0.3%)                   |
|                         | Salvage RT: 19 (6.8%)                  |
| Chemotherapy (N = 249)  | Adjuvant: 37 (14.9%) (TMZ, n = 7)      |
|                         | Not used: 208 (83.5%)                  |
|                         | Salvage-4 (1.6%)                       |
| Salvage treatment (N = 76) | Surgery: 20 (26.3%)                  |
|                         | Radiation: 13 (17.1%)                  |
|                         | Chemotherapy: 2 (2.6%)                 |
|                         | Surgery + RT: 13 (17.2%)               |
|                         | CT + RT: 7 (9.2%)                      |
|                         | Surgery + CT: 3 (3.9%)                 |
|                         | Surgery + RT + CT: 18 (23.7%)          |

Abbreviations: CT, chemotherapy; RT, radiotherapy; TMZ, temozolomide.
Discussion

XA has long been considered an indolent tumor entity. Because of the rarity of this tumor, there is a paucity of data regarding its clinical behavior and dilemma regarding the optimum treatment of these patients. In the absence of level I evidence, the individual patient data analysis was formulated to describe the demography, pattern of care, and survival outcome for XA. The survival and prognostic variables for Grade II XA has already been described in an earlier article. Hence, the present article aimed to compare survival and prognostic factors for Grade III XA with that of Grade II tumors as well. We retrieved 138 publications and derived individual patient data of 325 odd patients for the purpose of the analysis. Interestingly, only 7 publications had a sample size of more than 10.

For the entire cohort of XA, median age was 19 years. Our previous analysis of Grade II XA highlights the median age of 20 years which is not different for the entire cohort as well. This clearly reflects that XA is predominantly a disease of the young adults. The present analysis revealed an impressive median OS of 209 months for Grade II tumors, while it was only 49 months for Grade III tumors. An earlier analysis of Grade II and Grade III XA reported similar median survival. Univariate analysis also pointed toward a better prognostic outcome for older patients (>20 years) compared with the younger patients (<20 years). Eighty-two percent of the cases are diagnosed up to the age of 40 years with isolated cases in different ages beyond 40 years.

A Surveillance, Epidemiology, and End Results (SEER) data analysis and our previous analysis highlight the importance of surgery in particular importance of achieving a GTR. Although, in multivariate analysis, extent of surgery was not significant in the SEER analysis, it was significant in the analysis for Grade II tumors. The most important limitation of interpreting the surgical extent is variation of surgeons, different centers with variable experience, and in long period ways of interpretation of completeness of surgery. In addition, surgical standards have improved over the last few years with modern techniques such as intraoperative magnetic resonance imaging (MRI), awake craniotomy, and postoperative MRI. With the limitations of all these variables, the present analysis revealed significant impact of a GTR both on PFS (HR 2.19, p = 0.019) and OS (HR 1.72, p = 0.017). These findings clearly highlight the importance of achieving a GTR in XA. The analysis also highlights the importance of referring such patients to a center with expertise for better management.

However, the impact of adjuvant radiation was not a significant factor influencing OS or PFS. However, point should also be made that many of the patients have received radiation in poor performance status or with a large tumor. Furthermore, a possibility of publication bias cannot be ignored. This also highlights adopting a risk adopted treatment approach for lower and higher grade tumors. Hence, a GTR should be optimum for a lower grade tumor but a higher grade tumor merits more aggressive therapy with adjuvant radiotherapy or a combination of radiotherapy and chemotherapy should be advocated.

Because of excellent treatment outcome, long-term squeal and neurocognitive function is very important for these patients and every effort should be made to assure a better quality of life for patients with XA. In addition, follow-up protocol should also be carefully designed. As local recurrence is predominant, a contrast-enhanced MRI of brain...
every 3 months for the first 3 years and thereafter 6 monthly for 2 years and then annually should be optimum.

In the recent years, great enthusiasm has been witnessed in exploring the molecular pattern of XA. Different reports have demonstrated nearly V600E BRAF mutation in nearly 70% patients which constitutively activates RAS/RAF/MEK/ERK signaling pathway. Different BRAF inhibitors such as vemurafenib and dabrafenib have shown promising results in the management of recurrent XA. The present analysis revealed 58% BRAF mutation rate which makes it an interesting target for recurrent cases.

The analysis reveals many important facts about the rare tumor. We found significantly improved survival outcome for patients treated with a GTR than those with STR. Similarly, both PFS and OS favored patients with a Grade II tumor, younger age. However, the impact of adjuvant therapy was not clearly beneficial. Note should be made that nearly 47.7% patients experience disease progression at a median follow-up of nearly 3 years. Hence, risk stratification should be done and adjuvant radiation and chemotherapy may be advocated for high-risk patients.

This analysis has few limitations as well. As the individual patient data has been extracted from publication over a long period of time, a temporal bias is paramount importance. In this time frame, diagnostic criteria, surgical skill, and treatment approach have changed which may have definite impact on the quality of report. In addition, the publications included in the analysis are retrospective which also add to different types of bias. Because of inhomogeneity in reporting the cases, all relevant data pertaining to each case were not retrieved. This also forced us to conduct analysis on available fraction of data for fewer parameters. The use of individual patient characteristics for analysis may be considered as one of the merits of this work.

**Conclusion**

XA is a disease of young adults with favorable prognosis. Younger patients (<20 years), patients who undergo a GTR, and patients with a lower grade tumor have a better treatment outcome. The role of adjuvant therapy is debatable. However, in Grade III and incompletely resected tumors, adjuvant radiation of a combination of both radiotherapy and chemotherapy should be delivered. Whole genome sequencing should be performed to identify patients with different clinical behavior and treat accordingly.

**Funding**
None.

**Conflict of Interest**
None declared.

**References**
1. Mallick S, Benson R, Melgandi W, Giridhar P, Rath GK. Grade II pleomorphic xanthoastrocytoma: a meta-analysis of data from previously reported 167 cases. J Clin Neurosci 2018;54:57–62
2. Hamlat A, Le Strat A, Guegan Y, Ben-Hassel M, Saiakali S. Cerebellar pleomorphic xanthoastrocytoma: case report and literature review. Surg Neurol 2007;68(1):89–94, discussion 94–95
3. Adeleye AO, Okolo CA, Akang EE, Adesina AM. Cerebral pleomorphic xanthoastrocytoma associated with NF1: an updated review with a rare atypical case from Africa. Neurosurg Rev 2012;35(3):313–319, discussion 319
4. Aisner DL, Newell KL, Pollack AG, et al. Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases. Clin Neuropathol 2014;33(2):112–121
5. Alexandrescu S, Korshunov A, Lai SH, et al. Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas – same entity or first cousins? Brain Pathol 2016;26(2):215–223
6. Alexiou GA, Moschovi M, Stefanaki K, Prodromou C, Sfakianos G, Prodromou N. Malignant progression of a pleomorphic xanthoastrocytoma in a child. Neuropediatrics 2010;41(2):69–71
7. Arita K, Kurisu K, Tominaga A, Sugiyama K, Sumida M, Hirose T. Intrasellar pleomorphic xanthoastrocytoma: case report. Neurosurgery 2002;51(4):1079–1082, discussion 1082
8. Asano K, Miyamoto S, Kubo O, Kikukawa T, Yagihashi A, Ohkuma H. A case of anaplastic pleomorphic xanthoastrocytoma presenting with tumor bleeding and cerebrospinal fluid dissemination. Brain Tumor Pathol 2006;23(1):55–63
9. Bayindir C, Balak N, Karasu A, Kasaroğlu D. Anaplastic pleomorphic xanthoastrocytoma. Childs Nerv Syst 1997;13(1):50–56
10. Benjamin C, Faustin A, Snuderl M, Pacione D. Anaplastic pleomorphic xanthoastrocytoma with spinal leptomeningeal spread at the time of diagnosis in an adult. J Clin Neurosci 2015;22(8):1370–1373
11. Binesh F, Akhavan A, Navabii H. Pleomorphic xanthoastrocytoma with malignant transformation and multiple recurrences in an Iranian girl. BMJ Case Rep 2012
12. Bleggi-Torres LF, Gasparetto EL, Faoro LN, et al. Pleomorphic xanthoastrocytoma: report of a case diagnosed by intraoperative cytopathological examination. Diagn Cytopathol 2001;24(2):120–122
13. Brown NF, Carter T, Mulholland P. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma. CNS Oncol 2017;6(1):5–9
14. Bucciero A, De Caro MI, Tedeschi E, et al. Atypical pleomorphic xanthoastrocytoma. J Neurosurg Sci 1998;42(3):153–157
15. Chacko G, Chacko AG, Dunham CP, Judkins AR, Biegel JA, Perry A. Atypical teratoid/rhabdoid tumor arising in the setting of a pleomorphic xanthoastrocytoma. J Neurooncol 2007;84(2):217–222
16. Chakrabarty A, Mitchell P, Bridges LR, Franks AJ. Malignant transformation in pleomorphic xanthoastrocytoma—a report of two cases. Br J Neurosurg 1999;13(5):516–519
17. Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol 2013;114(2):237–240
18. Chang HT, Latorre JG, Hahn S, Dubowy R, Schelper RL. Pediatric cerebellar pleomorphic xanthoastrocytoma with anaplastic features: a case of long-term survival after multimodality therapy. Childs Nerv Syst 2006;22(6):609–613
19. Chapman EM, Ranger A, Lee DH, Hammond RR. A 15 year old boy with a posterior fossa tumor. Brain Pathol 2009;19(2):349–352
20. Charbel FT. Pleomorphic xanthoastrocytoma with malignant progression. Surg Neurol 1998;50(4):385–386
21. Choudry UK, Khan SA, Qureshi A, Bari E. Primary anaplastic pleomorphic xanthoastrocytoma in adults. Case report and review of literature. Int J Surg Case Rep 2016;27:183–188
22. Cicuendez M, Martinez-Saez E, Martinez-Ricarte F, Asanza EC, Sahuquillo J. Combined pleomorphic xanthoastrocytoma-gangliogioma with BRAF V600E mutation: case report. J Neurosurg Pediatr 2016;18(1):53–57
23 Das S, Yip S, Hukin J, Cochrane D, Dunham C. Pleomorphic xanthoastrocytoma of the spinal cord: case report and literature review. Clin Neuropathol 2014;33(3):190–196
24 de Tella OI, Jr, Herculano MA, Prandini MN, Stavale JN, Aguiar PH. Malignant transformation of pleomorphic xanthoastrocytoma: case report. Arq Neuropsiquiatr 2003;61(1):104–106
25 Ebato M, Tsunoda A, Maruki C, Ikeya F, Okada M. Distinctive pleomorphic xanthoastrocytoma-like tumor with exclusive abortive or aberrant neuronal differentiation and repeated recurrence—case report. Neurol Med Chir (Tokyo) 2002;42(9):399–405
26 Etzil MM, Jr, Kaplan AM, Moss SD, et al. Positron emission tomography in three children with pleomorphic xanthoastrocytoma. J Child Neurol 2002;17(7):522–527
27 Evans AJ, Fayaz I, Cusimano MD, Lapierriere N, Bilbao JM. Combined pleomorphic xanthoastrocytoma-gangliogioma of the cerebellum. Arch Pathol Lab Med 2000;124(11):1707–1709
28 Foo J, Ng WH. Metastatic pleomorphic xanthoastrocytoma in the scalp. J Clin Neurosci 2011;18(4):565–567
29 Fouladi M, Jenkins J, Burger P, et al. Pleomorphic xanthoastrocytoma: favorable outcome after complete surgical resection. Neuro-oncol 2001;3(3):184–192
30 Frank S, Cordier D, Tlalnay M, Rosenblum MKA. A 28-year-old man with headache, visual and aphasic speech disturbances. Brain Pathol 2009;19(1):163–166
31 Fu YJ, Miyahara H, Uzuka T, et al. Intraventricular pleomorphic xanthoastrocytoma with anaplastic features. Neuropathology 2010;30(4):443–448
32 Furuta A, Takahashi H, Ikuta F, Onda K, Takeda N, Tanaka R. Temporal lobe tumor demonstrating gangliogioma and pleomorphic xanthoastrocytoma components. Case report. J Neurosurg 1992;77(1):143–147
33 Gelpi E, Popovic M, Preusser M, Budka H, Hainfellner J. Pleomorphic xanthoastrocytoma with anaplastic features presenting without GFAP immunoreactivity: implications for differential diagnosis. Neuropathology 2005;25(3):241–246
34 Gill M, Pathak HC, Madan R, Bhattacharya S, Choudhary GS. Primary spinal pleomorphic xanthoastrocytoma. Neurol India 2010;58(5):771–773
35 Glasser RS, Rojiani AM, Mickel JP, Eskin TA. Delayed occurrence of cerebellar pleomorphic xanthoastrocytoma after subtotal surgical resection: case report. J Neurosurg 1995;82(1):116–118
36 Goldring S, Rich KM, Picker S. Experience with gliomas in patients presenting with a chronic seizure disorder. Clin Neurosurg 1999;46:35–42
37 Gonçalves VT, Reis F, Queiroz LdE, França M, Jr. Pleomorphic xanthoastrocytoma: magnetic resonance imaging findings in a series of cases with histopathological confirmation. Arq Neuropsiquiatr 2013;71(1):35–39
38 Gupta RK, Saran RK, Sharma MC, Srivastava AK, Garg L. Mesial temporal lobe epilepsy in pleomorphic xanthoastrocytoma: evidence for neuronal-glial origin: a case report with review of the literature. Neuropathology 2017;37(2):116–121
39 Hashmi M, Jaffari AA, Siddiqi SA, et al. Pleomorphic xanthoastrocytoma: an atypical astrocytoma. J Pak Med Assoc 2012;62(2):175–177
40 Hattab EM, Martin SE, Shapiro SA, Cheng L. Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components. J Neurosurg 2011;114(6):1648–1653
41 Herpers MJ, Feuling G, Beuls EA. Pleomorphic xanthoastrocytoma in the spinal cord. Case report. J Neurosurg 1994;80(3):564–569
42 Hirose T, Ishizawa K, Sugiyama K, Kageji T, Ueki K, Kannuki S. Pleomorphic xanthoastrocytoma: a comparative pathological study between conventional and anaplastic types. Histopathology 2008;52(2):183–193
43 Hong CS, Wang JL, Dornbos D, Ill, Joehlin-Price A, Elder J. BRAF-mutated pleomorphic xanthoastrocytoma of the spinal cord with eventual anaplastic transformation. World Neurosurg 2017;98:871.e9–871.e15
44 Horiguchi S, Mitsuya K, Watanabe R, Yagishita S, Nakasu Y. Pleomorphic xanthoastrocytoma and moyamoya disease in a patient with neurofibromatosis type I - case report. Neurol Med Chir (Tokyo) 2011;51(4):310–314
45 Im SH, Chung CK, Kim SK, Cho BK, Kim MK, Chi JG. Pleomorphic xanthoastrocytoma: a developmental glioneuronal tumor with prominent glioproliferative changes. J Neurooncol 2004;66(1-2):17–27
46 Iwaki T, Fukui M, Kondo A, Matsuotani T, Takeshita I. Epithelioid pleomorphic xanthoastrocytoma like tumor with exclusive abortive or aberrant neuronal differentiation and repeated recurrence—case report. Neurol Med Chir (Tokyo) 2011;51(4):310–314
47 Jea A, Ragheb J, Morrison G. Unique presentation of pleomorphic xanthoastrocytoma as a lytic skull lesion in an eight-year-old girl. Pediatr Neurosurg 2002;37(5):254–257
48 Jeong JY, Suh YL, Hong SW. Atypical teratoid/rhabdoid tumor arising in pleomorphic xanthoastrocytoma: a case report. Neuropathology 2014;34(4):398–405
49 Jiang CY, Yu JH, Zhang XY, Qi XL, Sun YS. Pleomorphic xanthoastrocytoma arising from the suprasellar region: a report of two cases. J Clin Neurosci 2016;33:228–231
50 Jiang YF, Liu Y, Wang YL, et al. Angiomatous pleomorphic xanthoastrocytoma: a case report and literature review. Diagn Pathol 2016;11(1):73
51 Jiménez-Heffernan JA, Freihr Fライア, Álvarez F, Bárzana C, Corbacho C. Cytologic features of pleomorphic xanthoastrocytoma, WHO grade II. A comparative study with glioblastoma. Diagn Cytopathol 2017;45(4):339–344
52 Kakui MV, Bhat DJ, Shukla D, Mahadevan A, Devi BL. Pleomorphic xanthoastrocytoma arising from olfactory groove: a rare location for a rare tumor. Pediatr Neurosurg 2013;49(5):292–296
53 Katayama K, Asano K, Shimamura N, et al. Case of pleomorphic xanthoastrocytoma with anaplastic features in the pineal gland. Brain Tumor Pathol 2013;30(4):242–246
54 Kepes JJ, Rubinstein LJ, Ansbacher L, Schreiber DJ. Histopathological features of recurrent pleomorphic xanthoastrocytomas: further corroboration of the glial nature of this neoplasm. A study of 3 cases. Acta Neuropathol 1989;78(6):585–593
55 Kim B, Chung CK, Myung JK, Park SH. Pleomorphic xanthoastrocytoma associated with long-standing Taylor-type IIb focal cortical dysplasia in an adult. Pathol Res Pract 2009;205(2):113–117
56 Koga T, Morita A, Maruyama K, et al. Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. Neuro-oncol 2009;11(4):446–451
57 Kordek R, Biennet W, Alwasiak J, Liberski P. Pleomorphic xanthoastrocytoma and desmoplastic infantile gangliogioma—have these neoplasms a common origin? Folia Neuropathol 2009;35:97
58 Krossnes BK, Mella O, Wester K, Mørk SJ. Pigmented astrocytoma with suprasellar location: case report and literature review. Acta Neuropathol 2004;108(5):461–466
59 Kumar S, Rentnam TM, Menon G, Nair S, Bhattacharya RN, Radhakrishnan VV. Cerebellar hemisphere, an uncommon location for pleomorphic xanthoastrocytoma and lipidized glioblastoma multiforme. Neurol India 2003;51(2):246–247
60 Kurschel S, Lenelloch-Tubiana A, Kulkarni AV, Sainte-Rose C. Pleomorphic xanthoastrocytoma of the cerebellopontine angle in a child. Childs Nerv Syst 2006;22(11):1479–1482
61 Lach B, Duggal N, DaSilva VF, Benoit BG. Association of pleomorphic xanthoastrocytoma with cortical dysplasia and neuronal tumors. A report of three cases. Cancer 1996;78(12):2551–2563
Demography, Pattern of Care, and Survival in Patients with Xanthoastrocytoma

Mallick et al.

62 Lacoste-Collin L, d’Aure D, Aziza J, Quintyn ML, Uro-Coste E, Courtade-Saidi M. Cerebospinal fluid cytologic findings of a pleomorphic xanthoastrocytoma: a case report. Acta Cytol 2010;54(5, Suppl):871–874
63 Lee EQ, Ruland S, LeBoeuf NR, Wen PY, Santagata S. Successful treatment of a progressive BRAF V600E-mutated anaplastic pleomorphic xanthoastrocytoma with vemurafenib monotherapy. J Clin Oncol 2016;34(10):e87–e89
64 Leonard N, Alcutt DA, Farrell MA, Fatal pleomorphic xanthoastrocytoma with meningial glioma. Histopathology 1998;32(4):375–378
65 Lim S, Kim JH, Kim SA, Park ES, Ra YS, Kim CJ. Prognostic factors and therapeutic outcomes in 22 patients with pleomorphic xanthoastrocytoma. J Korean Neurowsoc 2013;53(5):281–287
66 Lim SC, Jang SJ, Kim YS. Cerebellar pleomorphic xanthoastrocytoma in an infant. Pathol Int 1999;49(9):811–815
67 Lindboe CF, Cappelen J, Kepes JJ. Pleomorphic xanthoastrocytoma as a component of a cerebellar ganglioglioma: case report. Neurosurgery 1992;31(2):353–355
68 Lubansu A, Rosive S, David P, et al. Cerebral anaplastic pleomorphic xanthoastrocytoma with meningal dissemination at first presentation. Childs Nerv Syst 2004;20(6):119–122
69 Macaulay RJ, Jay V, Hoffman HJ, Becker LE. Increased mitotic activity as a negative prognostic indicator in pleomorphic xanthoastrocytoma. Case report. J Neurol Surg 1993;79(5):761–768
70 Martin AG, Singh MS, Idris B, Abdullah JM. Pleomorphic xanthoastrocytoma in a case of tuberous sclerosis. J Neurolsci Rural Pract 2014;5(3):258–260
71 Marton E, Feletti A, Orvieto E, Longatti P. Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature. J Neurol Sci 2007;252(2):144–153
72 Mascalchi M, Muscas GC, Galli C, Bartolozzi C. MRI of pleomorphic xanthoastrocytoma: case report. Neuroradiology 1994;36(6):446–447
73 McNatt SA, Gonzalez-Gomez I, Nelson MD, McComb JC. Synchronous multicentric pleomorphic xanthoastrocytoma: case report. Neurosurgery 2005;57(1):E191
74 Menendez R, Fernandez J, Monti A, Sevelger G. Intraventricular pleomorphic xanthoastrocytoma: a case report. Turk Neurosurg 2014;24(6):987–991
75 Miyagi Y, Suzuki SO, Iwaki T, et al. Pleomorphic xanthoastrocytoma with predominantly exophytic growth: case report. Surg Neurol 2001;56(5):330–332
76 Montano N, Papacci F, Cioni B, et al. Primary multicentric anaplastic pleomorphic xanthoastrocytoma with atypical features. J Clin Neuosci 2013;20(11):1605–1608
77 Moore W, Mathis D, Gargan L, et al. Pleomorphic xanthoastrocytoma of childhood: MR imaging and diffusion MR imaging features. AJNR Am J Neuroradiol 2014;35(11):2192–2196
78 Naganska E, Matyja E, Pucko M, Zabek M. The coexistence of pleomorphic xanthoastrocytoma and ganglioglioma. Report of a case. Folia Neuropathol 2013;51(3):269–274
79 Naidich MJ, Walker MT, Gottardi-Littell NR. Han G, Prayson RA. Pleomorphic xanthoastrocytoma arising in neurofibromatosis type 1. J Clin Neuropathol 2013;32(1):54–56
80 Nakajima T, Kumabe T, Shamoto H, Watanabe M, Suzuki H, Tominaga T. Malignant transformation of pleomorphic xanthoastrocytoma. Acta Neurochir (Wien) 2006;148(1):67–71
81 Nakamura M, Chiha K, Matsumoto M, Ikeda E, Toyama Y. Pleomorphic xanthoastrocytoma of the spinal cord. Case report. J Neurosurg Spine 2006;5(1):72–75
82 Nasuha NA, Daud AH, Ghazali MM, et al. Molecular genetic analysis of anaplastic pleomorphic xanthoastrocytoma. Asian J Surg 2003;26(2):120–125
83 Neal MT, Ellis TL, Stanton CA. Pleomorphic xanthoastrocytoma in two siblings with neurofibromatosis type 1 (NF-1). Clin Neuropathol 2012;31(1):54–56
84 Nern C, Hench J, Fischmann A. Spinal imaging in intracranial primary pleomorphic xanthoastrocytoma with anaplastic features. J Clin Neurosci 2012;19(9):1299–1301
85 Ng WH, Lim T, Yeo TT. Pleomorphic xanthoastrocytoma in elderly patients may portend a poor prognosis. J Clin Neurosci 2008;15(4):476–478
86 Niamathulla S, Sivaseelan M, Ghosh M, Ghosh S. Pleomorphic xanthoastrocytoma with anaplastic features: a case report. Indian J Pathol Microbiol 2014;57(1):101–104
87 Oh T, Kaur G, Madden M, Bloch O, Parsa AT. Pleomorphic xanthoastrocytomas: institutional experience of 18 patients. J Clin Neurosci 2014;21(10):1767–1772
88 Okazaki T, Kageji T, Matsuzaki K, et al. Primary anaplastic pleomorphic xanthoastrocytoma with widespread neuroaxis dissemination at diagnosis—a pediatric case report and review of the literature. J Neuurooncol 2009;94(3):431–437
89 Passone E, Pizzolitto S, D’Agostini S, et al. Non-anaplastic pleomorphic xanthoastrocytoma with neuroradiological evidence of leptomeningeal dissemination. Childs Nerv Syst 2006:22(6):614–618
90 Patibanda MR, Nayak M, Purohit AK, Thakatura AK, Uppin M, Challa S. Pleomorphic xanthoastrocytoma with anaplastic features: a rare case report and review of literature with reference to current management. Asian J Neurosurg 2016;11(3):319
91 Paulus W, Lisle DK, Tonn JC, et al. Molecular genetic alterations in pleomorphic xanthoastrocytoma. Acta Neuropatholog 1996;91(3):293–297
92 Perry A, Giannini C, Scheithauer BW, et al. Composite pleomorphic xanthoastrocytoma and ganglioglioma: report of four cases and review of the literature. Am J Surg Pathol 1997;21(7):763–771
93 Perry A, Scheithauer BW, Szczesniak DM, Atkinson JL, Wald JT, Hammad JE. Combined oligodendroglioma/pleomorphic xanthoastrocytoma: a probable collision tumor: case report. Neurosurgery 2001;48(6):1358–1361
94 Prayson RA. Pleomorphic xanthoastrocytoma arising in neurofibromatosis Type 1. Clin Neuropathol 2012;31(3):152–154
95 Ramelli GP, von der Weid N, Remonda L, Mariani L, Weiss J. Pleomorphic xanthoastrocytoma derived from glioneuronal malformation in a child with intractable epilepsy. J Child Neurol 2000;15(4):270–272
96 Rao AA, Laack NN, Giannini C, Wetmore C. Pleomorphic xanthoastrocytoma in children and adolescents. Pediatr Blood Cancer 2010;55(2):290–294
97 Razzaq AA, Akula M, Mathew B. Unusual recurrence of pleomorphic xanthoastrocytoma in children in two siblings with neurofibromatosis type 1. J Clin Neurosci 2014;21(10):1767–1772
98 Ramelli GP, von der Weid N, Remonda L, Mariani L, Weiss J. Pleomorphic xanthoastrocytomas: institutional experience of 18 patients. J Clin Neurosci 2005;12(6):375–378
99 Razzaq AA, Akula M, Mathew B. Unusual recurrence of pleomorphic xanthoastrocytoma in children in two siblings with neurofibromatosis type 1. J Clin Neurosci 2014;21(10):1767–1772
100 Rutkowski MJ, Oh T, Niflioglu GG, Safaei M, Tihan T, Parsa AT. Pleomorphic xanthoastrocytoma with anaplastic features: A prospective case series. World Neurosurg 2016;95:368–374
101 Saikali S, Le Strat A, Heckly A, Stock N, Scarabin JM, Hamlat A. Multicentric pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1. Case report and review of the literature. J Neurosurg 2005;102(2):376–381
102 Sawyer JR, Roloson GJ, Chadduck WM, Boop FA. Cytogenetic findings in a pleomorphic xanthoastrocytoma. Cancer Genet Cytogenet 1991;55(2):225–230

436
103 Sezer S, Baykan A, Yilmaz E, et al. Atrial fibrillation as an uncommon presentation in a large pleomorphic xanthoastrocytoma. Childs Nerv Syst 2012;28(3):475–479

104 Sharma M, Chaudhery S, Sonig A, Ambekar S, Nanda A. Does the occurrence of pleomorphic xanthoastrocytoma in the elderly carries a poor prognosis: a case report and review of literature. Asian J Neurosurg 2014;9(4):237

105 Sharma MC, Arora R, Khanna N, Singh VP, Sarkar C. Pigmented pleomorphic xanthoastrocytoma: report of a rare case with review of the literature. Arch Pathol Lab Med 2001;125(8):808–811

106 Simal-Jullian JA, Sanchis-Martín R, Prat-Acín R, et al. Spinal pleomorphic xanthoastrocytoma. Case report [in Spanish]. Neurocirugia (Astur) 2010;21(5):390–395

107 Srinivas BH, Uppin MS, Panigrahi MK. Vijaya Saradhi M, Jyotsna Rani Y, Challa S. Pleomorphic xanthoastrocytoma of the pineal region. J Clin Neurosci 2010;17(11):1439–1441

108 Stuart G, Appleton DB, Cooke R. Pleomorphic xanthoastrocytoma: report of two cases. Neurosurgery 1988;22(2):422–427

109 Sugita Y, Irie K, Ohshima K, Hitosumatsu T, Sato O, Arimura K. Pleomorphic xanthoastrocytoma as a component of a temporal lobe cystic ganglioglioma: a case report. Brain Tumor Pathol 2006;26(1):31–36

110 Sugita Y, Shigemori M, Okamoto K, Morimatsu M, Arakawa M, Nakayama K. Clinicopathological study of pleomorphic xanthoastrocytoma: correlation between histological features and prognosis. Pathol Int 2000;50(9):703–708

111 Sundaram C, Naidu MR, Reddy J. Pleomorphic xanthoastrocytoma–a clinicopathological study. Indian J Pathol Microbiol 2000;43(3):357–361

112 Suzuki Y, Akilya Y, Kimura Y, Sugita S, Hasegawa T, Mikuni N. Pleomorphic xanthoastrocytoma with anaplastic features in the Tectal region in a young adult patient: a case report. World Neurosurg 2016;94:580.e11–580.e15

113 Takei H, Rouah E, Bhattacharjee MB. Cerebellar pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1: a case report and literature review. Int J Clin Exp Pathol 2015;8(6):7570–7574

114 Tan TC, Ho LC, Yu CP, Cheung FC. Pleomorphic xanthoastrocytoma: report of two cases and review of the prognostic factors. J Clin Neurosci 2004;11(2):203–207

115 Tonn JC, Paulus W, Warmuth-Metz M, Schachenmayr W, Sörensen N, Roos S, Kreis K. Pleomorphic xanthoastrocytoma: report of six cases with special consideration of diagnostic and therapeutic pitfalls. Surg Neurol 1997;47(2):162–169

116 Tsutsumi S, Abe Y, Yasumoto Y, Ito M. Anaplastic pleomorphic xanthoastrocytoma with component of anaplastic astrocytoma presented as skull base tumor followed by downward extracranial extension. Case report. Neurol Med Chir (Tokyo) 2010;50(12):1108–1112

117 Tsuyuguchi N, Matsuoka Y, Sunada I, Matsuoka Y, Haque M. Evaluation of pleomorphic xanthoastrocytoma by use of positron emission tomography with [18F]FDG. AJNR Am J Neuroradiol 2001;22(2):311–313

118 Usbulaliev A, Pierson CR, Kavran CA, et al. Primary meningeval pleomorphic xanthoastrocytoma with anaplastic features: a report of 2 cases, one with BRAF(V600E) mutation and clinical response to the BRAF inhibitor dabrafenib. J Neuropathol. Exp Neurol 2015;74(10):960–969

119 Vajtai I, Stibal A, von Gunten M, Kappeler A, Vassella E, Frank S. Glycogen-rich pleomorphic xanthoastrocytoma with clear-cell features: confirmatory report of a rare variant with implications for differential diagnosis. Pathol Res Pract 2011;207(4):256–261

120 Vajtai I, Varga Z, Aguzzi A. Pleomorphic xanthoastrocytoma with gangliogliomatous component. Pathol Res Pract 1997;193(9):617–621

121 van Roost D, Kristof R, Zentner J, Wolf HK, Schramm J. Clinical, radiological, and therapeutic features of pleomorphic xanthoastrocytoma: report of three patients and review of the literature. J Neurol Neurosurg Psychiatry 1996;60(6):690–692

122 Vizcaíno MA, Caccamo DV, Fox E, Rodriguez FJ. Pleomorphic xanthoastrocytoma: report of two cases with unconventional clinical presentations. Clin Neuropathol 2014;33(6):380–387

123 Vyas A, Mathé M, Dravet C, Valerio M, Charvet JY, Majoie CCR. Anaplastic pleomorphic xanthoastrocytoma: report of a case. Childs Nerv Syst 2012;28(12):2071–2075

124 Wallace DJ, Byrne RW, Ruban D, Cochran Ej, Roh D, Whisler WW. Temporal lobe pleomorphic xanthoastrocytoma and chronic epilepsy: long-term surgical outcomes. Clin Neurosurg 2011;113(10):918–922

125 Wasdahl DA, Scheithauer BW, Andrews BT, Jeffrey RA. J. cerebellar pleomorphic xanthoastrocytoma: case report. Clin Neuropathol 2000;19:238–242

126 Whittle IR, Gordon A, Misra BK, Shaw JF, Steers AJ. Pleomorphic xanthoastrocytoma. Report of four cases. J Neurol Neurosurg Psychiatry 1989;70(3):463–468

127 Wind J, Kerr PB, Sweet JA, Deshmukh VR. Pleomorphic xanthoastrocytoma presenting with life-threatening hemorrhage in a child. J Neurol Neurosurg Pediatr 2009;3(2):157–159

128 Xiong J, Chu SG, Mao Y, Wang Y. Pigmented pleomorphic xanthoastrocytoma: a rare variant and literature review. Neuropathology 2011;31(1):88–92

129 Yamada SM, Murakami H, Tomita Y, et al. Gioblastoma multiforme versus pleomorphic xanthoastrocytoma with anaplastic features in the pathological diagnosis: a case report. Diagn Pathol 2016;11:1:65

130 Yang MM, Singhal A, Rassah SK, Yip S, Eydoux P, Dunham C. Possible differentiation of cerebral glioblastoma into pleomorphic xanthoastrocytoma: an unusual case in an infant. J Neurol Neurosurg Pediatr 2012;85(5):517–521

131 Yang WQ, Huang B, Liang CH. Pleomorphic xanthoastrocytoma in the lateral ventricle with extensive subarachnoid dissemination: report of a case and review of the literature. Chin Med J (Engl) 2012;125(2):396–399

132 Yeh D, Hesser RB, Stevens EA, Lee MR. Composite pleomorphic xanthoastrocytoma-ganglioglioma presenting as a suprasellar mass: case report. Neurosurgery 2003;52(6):1465–1468, discussion 1468–1469

133 Yin XL, Hui AB, Liong EC, Ding M, Chang AR, Ng HK. Genetic imbalances in pleomorphic xanthoastrocytoma detected by comparative genomic hybridization and literature review. Cancer Genet Cyogenet 2002;132(1):14–19

134 Yoshikawa G, Kawamoto S, Yako K, Tsutsumi K. Massive intracranial hemorrhage associated with pleomorphic xanthoastrocytoma–case report. Neurol Med Chir (Tokyo) 2012;50(3):220–223

135 Yu S, He L, Zhuang X, Luo B. Pleomorphic xanthoastrocytoma: MR imaging findings in 9 patients. Acta Radiol 2011;52(2):223–228

136 Zakrzewska M, Szybka M, Biernat W, et al. Prevalence of mutated TP53 on cDNA (but not on DNA template) in pleomorphic xanthoastrocytoma. Case report. Cancer Genet Cyogenet 2002;132(1):14–19

137 Zhao X, Jiang X, Wang X. Spinal pleomorphic xanthoastrocytoma: report of a rare case with review of the literature. Asian J Neurosurg 2014;9(4):237

138 Zhuang Z, Lee YS, Zeng W, et al. Molecular genetic and proteomic analysis of synchronous malignant gliomas. Neurology 2004;62(12):2316–2319

139 Perkins SM, Mitra N, Fei W, Shinohara ET. Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: a SEER analysis. J Neurooncol 2012;110(1):99–104